IMD-Pharma hires Dr Emily Clement and Dr Abdelouahd Oukrib as biology and chemistry R&D managers respectively.
IMD-Pharma raises 840 k€ from private investors (BAs and WiSEED) to accelerate the development of its assets for the treatment of Rheumatoid Arthritis.
IMD-Pharma signs a hosting contract with the Inserm research unit U1291 (Infinity, Toulouse).
